BirnbaumG.Stopping disease-modifying therapy in nonrelapsing multiple sclerosis: Experience from a clinical practice. Int J MS Care2017; 19(1): 11–14.
2.
NagyGvan VollenhovenRF.Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?Arthritis Res Ther2015; 17: 181.
3.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85(2): 177–189.
4.
KleiterIGahlenABorisowN, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol2016; 79(2): 206–216.
5.
WingerchukDMHogancampWFO’BrienPC, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology1999; 53(5): 1107–1114.
CabrePGonzalez-QuevedoABonnanM, et al. Relapsing neuromyelitis optica: Long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry2009; 80(10): 1162–1164.
8.
WeinfurtnerKGravesJNessJ, et al. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol2015; 30(10): 1366–1370.
9.
WatersPJMcKeonALeiteMI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology2012; 78(9): 665–671; discussion 669.
10.
PanditLMustafaS.Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. Neurol Neuroimmunol Neuroinflamm2017; 4(4): e351.
